C
BioMarin Pharmaceutical Inc.
BMRN
$68.32
$0.380.56%
C
Hold
3/6/2025Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 3/6/2025 due to an increase in the valuation index, efficiency index and growth index. EBIT increased 125.86% from $113.89M to $257.24M, earnings per share increased from $0.5474 to $0.6449, and net income increased 17.78% from $106.08M to $124.94M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 3/6/2025 due to an increase in the valuation index, efficiency index and growth index. EBIT increased 125.86% from $113.89M to $257.24M, earnings per share increased from $0.5474 to $0.6449, and net income increased 17.78% from $106.08M to $124.94M.
D
Sell
12/3/2024Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 12/3/2024 due to a decline in the total return index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 12/3/2024 due to a decline in the total return index and volatility index.
C
Hold
11/4/2024Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 11/4/2024 due to a major increase in the growth index, efficiency index and valuation index. Operating cash flow increased 86.49% from $118.76M to $221.48M, and total revenue increased 4.73% from $712.03M to $745.74M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 11/4/2024 due to a major increase in the growth index, efficiency index and valuation index. Operating cash flow increased 86.49% from $118.76M to $221.48M, and total revenue increased 4.73% from $712.03M to $745.74M.
D
Sell
10/21/2024Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 10/21/2024 due to a decline in the growth index, volatility index and total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 10/21/2024 due to a decline in the growth index, volatility index and total return index.
C
Hold
8/5/2024Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 8/5/2024 due to a decline in the total return index, volatility index and efficiency index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 8/5/2024 due to a decline in the total return index, volatility index and efficiency index.
C
Hold
7/19/2024Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 7/19/2024 due to an increase in the volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 7/19/2024 due to an increase in the volatility index.
C
Hold
7/3/2024Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 7/3/2024 due to a decline in the volatility index, valuation index and total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 7/3/2024 due to a decline in the volatility index, valuation index and total return index.
C
Hold
6/12/2024Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 6/12/2024 due to an increase in the total return index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 6/12/2024 due to an increase in the total return index and volatility index.
C
Hold
5/28/2024Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 5/28/2024 due to a noticeable decline in the volatility index and total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 5/28/2024 due to a noticeable decline in the volatility index and total return index.
C
Hold
2/27/2024Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 2/27/2024 due to a large increase in the growth index and volatility index. Total revenue increased 11.16% from $581.33M to $646.21M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 2/27/2024 due to a large increase in the growth index and volatility index. Total revenue increased 11.16% from $581.33M to $646.21M.
C
Hold
11/21/2023Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 11/21/2023 due to an increase in the volatility index and total return index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 11/21/2023 due to an increase in the volatility index and total return index.
D
Sell
11/6/2023Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 11/6/2023 due to a large decline in the growth index, volatility index and efficiency index. EBIT declined 56.41% from $58.87M to $25.66M, net income declined 27.95% from $56.04M to $40.38M, and earnings per share declined from $0.2922 to $0.2112.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 11/6/2023 due to a large decline in the growth index, volatility index and efficiency index. EBIT declined 56.41% from $58.87M to $25.66M, net income declined 27.95% from $56.04M to $40.38M, and earnings per share declined from $0.2922 to $0.2112.
C
Hold
5/16/2023Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 5/16/2023 due to a decline in the volatility index and total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 5/16/2023 due to a decline in the volatility index and total return index.
C
Hold
5/1/2023Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 5/1/2023 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.0156 to $0.2665, EBIT increased 357.09% from -$23.9M to $61.45M, and total revenue increased 10.95% from $537.54M to $596.42M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 5/1/2023 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.0156 to $0.2665, EBIT increased 357.09% from -$23.9M to $61.45M, and total revenue increased 10.95% from $537.54M to $596.42M.
C
Hold
1/12/2023Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 1/12/2023 due to a decline in the total return index and valuation index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 1/12/2023 due to a decline in the total return index and valuation index.
C
Hold
12/28/2022Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 12/28/2022 due to a substantial increase in the total return index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 12/28/2022 due to a substantial increase in the total return index.
C
Hold
10/28/2022Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 10/28/2022 due to a major decline in the growth index, efficiency index and volatility index. Earnings per share declined from $0.1493 to -$0.04, net income declined 124.05% from $27.66M to -$6.65M, and EBIT declined 103.79% from $40.05M to -$1.52M.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 10/28/2022 due to a major decline in the growth index, efficiency index and volatility index. Earnings per share declined from $0.1493 to -$0.04, net income declined 124.05% from $27.66M to -$6.65M, and EBIT declined 103.79% from $40.05M to -$1.52M.
C
Hold
10/24/2022Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 10/24/2022 due to a large increase in the total return index, volatility index and efficiency index. Total capital increased 2.08% from $5.48B to $5.6B.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 10/24/2022 due to a large increase in the total return index, volatility index and efficiency index. Total capital increased 2.08% from $5.48B to $5.6B.
C
Hold
4/29/2022Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 4/29/2022 due to a significant increase in the growth index, volatility index and efficiency index. Net income increased 308.64% from -$57.9M to $120.8M, earnings per share increased from -$0.3188 to $0.634, and EBIT increased 148.85% from -$64.11M to $31.32M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 4/29/2022 due to a significant increase in the growth index, volatility index and efficiency index. Net income increased 308.64% from -$57.9M to $120.8M, earnings per share increased from -$0.3188 to $0.634, and EBIT increased 148.85% from -$64.11M to $31.32M.
D
Sell
11/24/2021Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 11/24/2021 due to a noticeable increase in the total return index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 11/24/2021 due to a noticeable increase in the total return index.
D
Sell
11/3/2021Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from C- on 11/3/2021 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 470.67% from $13.87M to -$51.42M, earnings per share declined from $0.07 to -$0.2, and net income declined 382% from $12.94M to -$36.49M.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from C- on 11/3/2021 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 470.67% from $13.87M to -$51.42M, earnings per share declined from $0.07 to -$0.2, and net income declined 382% from $12.94M to -$36.49M.
C
Hold
10/19/2021Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 10/19/2021 due to a decline in the volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 10/19/2021 due to a decline in the volatility index.
C
Hold
6/9/2021Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 6/9/2021 due to a noticeable increase in the solvency index, valuation index and volatility index. The quick ratio increased from 3.07 to 3.45.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 6/9/2021 due to a noticeable increase in the solvency index, valuation index and volatility index. The quick ratio increased from 3.07 to 3.45.
C
Hold
4/20/2021Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 4/20/2021 due to a decline in the valuation index, volatility index and total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 4/20/2021 due to a decline in the valuation index, volatility index and total return index.
C
Hold
4/5/2021Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 4/5/2021 due to an increase in the volatility index and valuation index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 4/5/2021 due to an increase in the volatility index and valuation index.
C
Hold
3/16/2021Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 3/16/2021 due to a noticeable decline in the solvency index, total return index and growth index. Operating cash flow declined 115.53% from $86.21M to -$13.38M, earnings per share declined from $4.006 to $0.0655, and total revenue declined 5.17% from $476.78M to $452.12M.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 3/16/2021 due to a noticeable decline in the solvency index, total return index and growth index. Operating cash flow declined 115.53% from $86.21M to -$13.38M, earnings per share declined from $4.006 to $0.0655, and total revenue declined 5.17% from $476.78M to $452.12M.
C
Hold
1/14/2021Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 1/14/2021 due to an increase in the volatility index, total return index and solvency index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 1/14/2021 due to an increase in the volatility index, total return index and solvency index.
C
Hold
11/9/2020Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D on 11/9/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 2,789.25% from -$29.18M to $784.8M, earnings per share increased from -$0.1615 to $4.006, and operating cash flow increased 210.8% from $27.74M to $86.21M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D on 11/9/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 2,789.25% from -$29.18M to $784.8M, earnings per share increased from -$0.1615 to $4.006, and operating cash flow increased 210.8% from $27.74M to $86.21M.
D
Sell
10/8/2020Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 10/8/2020 due to a noticeable decline in the total return index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 10/8/2020 due to a noticeable decline in the total return index and volatility index.
D
Sell
8/7/2020Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C on 8/7/2020 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 191.38% from $45.46M to -$41.55M, earnings per share declined from $0.4398 to -$0.1615, and debt to equity increased from 0.27 to 0.45.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C on 8/7/2020 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 191.38% from $45.46M to -$41.55M, earnings per share declined from $0.4398 to -$0.1615, and debt to equity increased from 0.27 to 0.45.
C
Hold
6/17/2020Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 6/17/2020 due to a noticeable increase in the total return index, solvency index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 6/17/2020 due to a noticeable increase in the total return index, solvency index and volatility index.
C
Hold
5/1/2020Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 5/1/2020 due to a large increase in the volatility index, total return index and efficiency index. Net income increased 441.67% from $15.02M to $81.38M, and total capital increased 3.01% from $4.03B to $4.15B.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 5/1/2020 due to a large increase in the volatility index, total return index and efficiency index. Net income increased 441.67% from $15.02M to $81.38M, and total capital increased 3.01% from $4.03B to $4.15B.
D
Sell
10/31/2019Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 10/31/2019 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 388.13% from -$24.34M to $70.13M, net income increased 247.02% from -$37.44M to $55.04M, and earnings per share increased from -$0.2091 to $0.3011.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 10/31/2019 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 388.13% from -$24.34M to $70.13M, net income increased 247.02% from -$37.44M to $55.04M, and earnings per share increased from -$0.2091 to $0.3011.
D
Sell
5/1/2019Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 5/1/2019 due to a decline in the volatility index and growth index. Earnings per share declined from -$0.0245 to -$0.32, and operating cash flow declined 211.13% from $49.37M to -$54.87M.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 5/1/2019 due to a decline in the volatility index and growth index. Earnings per share declined from -$0.0245 to -$0.32, and operating cash flow declined 211.13% from $49.37M to -$54.87M.
D
Sell
3/4/2019Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 3/4/2019 due to a major decline in the growth index and efficiency index. EBIT declined 1,353.77% from -$4.74M to -$68.92M, total revenue declined 9.83% from $391.71M to $353.21M, and total capital declined 7.7% from $4.12B to $3.8B.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 3/4/2019 due to a major decline in the growth index and efficiency index. EBIT declined 1,353.77% from -$4.74M to -$68.92M, total revenue declined 9.83% from $391.71M to $353.21M, and total capital declined 7.7% from $4.12B to $3.8B.
C
Hold
10/29/2018Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 10/29/2018 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 239.41% from -$33.86M to $47.2M, EBIT increased 88.86% from -$42.56M to -$4.74M, and earnings per share increased from -$0.0949 to -$0.0711.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 10/29/2018 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 239.41% from -$33.86M to $47.2M, EBIT increased 88.86% from -$42.56M to -$4.74M, and earnings per share increased from -$0.0949 to -$0.0711.
D
Sell
7/16/2018Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 7/16/2018 due to an increase in the volatility index, growth index and efficiency index. EBIT increased 28.51% from -$54.19M to -$38.74M, net income increased 14.09% from -$51.39M to -$44.15M, and earnings per share increased from -$0.2929 to -$0.2581.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 7/16/2018 due to an increase in the volatility index, growth index and efficiency index. EBIT increased 28.51% from -$54.19M to -$38.74M, net income increased 14.09% from -$51.39M to -$44.15M, and earnings per share increased from -$0.2929 to -$0.2581.
D
Sell
1/8/2018Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 1/8/2018 due to a decline in the volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 1/8/2018 due to a decline in the volatility index.
D
Sell
12/19/2017Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 12/19/2017 due to an increase in the total return index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 12/19/2017 due to an increase in the total return index and volatility index.
D
Sell
12/4/2017Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 12/4/2017 due to a decline in the solvency index, total return index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 12/4/2017 due to a decline in the solvency index, total return index and volatility index.
D
Sell
11/2/2017Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 11/2/2017 due to a large increase in the growth index, efficiency index and volatility index. Operating cash flow increased 103.9% from $18.78M to $38.29M, earnings per share increased from -$0.2112 to -$0.0715, and net income increased 65.99% from -$36.83M to -$12.53M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 11/2/2017 due to a large increase in the growth index, efficiency index and volatility index. Operating cash flow increased 103.9% from $18.78M to $38.29M, earnings per share increased from -$0.2112 to -$0.0715, and net income increased 65.99% from -$36.83M to -$12.53M.
D
Sell
7/17/2017Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 7/17/2017 due to a decline in the total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 7/17/2017 due to a decline in the total return index.
D
Sell
6/26/2017Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 6/26/2017 due to an increase in the total return index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 6/26/2017 due to an increase in the total return index and volatility index.
D
Sell
5/25/2017Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 5/25/2017 due to a decline in the total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 5/25/2017 due to a decline in the total return index.
D
Sell
5/10/2017Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 5/10/2017 due to a noticeable increase in the total return index, valuation index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to D+ from D on 5/10/2017 due to a noticeable increase in the total return index, valuation index and volatility index.
D
Sell
3/11/2016Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
D
Sell
10/19/2015Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 10/19/2015 due to a major decline in the total return index.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 10/19/2015 due to a major decline in the total return index.
C
Hold
8/24/2015Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 8/24/2015 due to a large decline in the volatility index, growth index and efficiency index. Operating cash flow declined 90.57% from -$137.81M to -$12.99M, EBIT declined 20.58% from -$62.88M to -$49.94M, and total capital declined 2.03% from $3.08B to $3.02B.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to C- from C on 8/24/2015 due to a large decline in the volatility index, growth index and efficiency index. Operating cash flow declined 90.57% from -$137.81M to -$12.99M, EBIT declined 20.58% from -$62.88M to -$49.94M, and total capital declined 2.03% from $3.08B to $3.02B.
C
Hold
1/12/2015Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 1/12/2015 due to a major increase in the total return index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C from C- on 1/12/2015 due to a major increase in the total return index and volatility index.
C
Hold
10/31/2014Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 10/31/2014 due to a noticeable increase in the volatility index, total return index and growth index. EBIT increased 236.78% from -$16.18M to -$54.5M.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 10/31/2014 due to a noticeable increase in the volatility index, total return index and growth index. EBIT increased 236.78% from -$16.18M to -$54.5M.
D
Sell
6/12/2014Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 6/12/2014 due to a major decline in the volatility index, total return index and efficiency index. Net income declined 38.51% from -$61.99M to -$38.12M.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 6/12/2014 due to a major decline in the volatility index, total return index and efficiency index. Net income declined 38.51% from -$61.99M to -$38.12M.
C
Hold
4/21/2014Upgraded
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 4/21/2014 due to an increase in the valuation index and volatility index.
BioMarin Pharmaceutical Inc. (BMRN) was upgraded to C- from D+ on 4/21/2014 due to an increase in the valuation index and volatility index.
D
Sell
3/31/2014Downgrade
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 3/31/2014 due to a decline in the solvency index and total return index. Debt to equity increased from 0.06 to 0.49.
BioMarin Pharmaceutical Inc. (BMRN) was downgraded to D+ from C- on 3/31/2014 due to a decline in the solvency index and total return index. Debt to equity increased from 0.06 to 0.49.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
